ArticleBiochemistry and biophysics reports2025
The LINC01270/miR-29c-3p/LOX axis drives gastric cancer progression: Bioinformatics and experimental validation.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Stiff Side of Cancer: How Matrix Mechanics Rewrites Non-Coding RNA Expression Programs.Non-coding RNA · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is the fifth most common cancer-related cause of death worldwide, characterized by high recurrence and mortality rates. Lysyl oxidase (LOX) has been implicated in GC progression, although its precise role remains unclear. Based on the competing endogenous RNA (ceRNA) hypothesis, this study aimed to identify a lncRNA-miRNA axis regulating LOX overexpression in GC. Through integrated analysis of microarray data, bioinformatics databases, and online prediction tools, we identified TUG1 and the LINC01270-miR-29c-3p axis as a novel upstream ceRNA network regulating LOX expression. These findings were validated in GC tissues and KATO III cells, where LINC01270 and LOX were significantly upregulated and inversely correlated with miR-29c-3p expression. To assess the functional relevance of this axis, we silenced LINC01270 using siRNA in KATO III cells, resulting in increased miR-29c-3p expression, decreased LOX levels, and reduced cell viability. These results suggest that LINC01270 promotes GC progression by sponging miR-29c-3p, thereby upregulating LOX, and highlight the LINC01270-miR-29c-3p-LOX axis as a potential diagnostic and therapeutic target in GC. Furthermore, LOX, LINC01270, and miR-29c-3p may serve as potential diagnostic and prognostic biomarkers in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.